Life Saving Drugs Program – Mucopolysaccharidosis type VI (MPS VI) – Guidelines
We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.
These guidelines include:
- General information about the Life Saving Drugs Program (LSDP)
- Treatment of mucopolysaccharidosis type VI (MPS VI) through the LSDP
- Drugs currently available for the treatment of MPS VI through the LSDP
- General, initial and ongoing eligibility requirements
- LSDP funding conditions
- Exclusion criteria.